<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02279914</url>
  </required_header>
  <id_info>
    <org_study_id>Miso</org_study_id>
    <nct_id>NCT02279914</nct_id>
  </id_info>
  <brief_title>Misoprostol Dose and Timing Before Surgical Abortion at 13 to 16 Weeks' Gestation: a Randomized Trial</brief_title>
  <official_title>Misoprostol Dose and Timing Before Surgical Abortion at 13 to 16 Weeks' Gestation: a Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Planned Parenthood of Greater New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Planned Parenthood of Greater New York</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a blinded randomized trial to compare two different doses and intervals of&#xD;
      buccal misoprostol for cervical preparation before surgical abortion at 13 to 16 weeks'&#xD;
      gestation: 400 mcg administered 3 hours before D&amp;E (dilation and extraction), and 600 mcg&#xD;
      administered 1.5 hours before D&amp;E.&#xD;
&#xD;
      Primary objective: To compare operative times after two different doses and intervals of&#xD;
      misoprostol using a non-inferiority design.&#xD;
&#xD;
      Secondary objectives: To compare the doses and intervals of misoprostol for differences in:&#xD;
      (1) initial cervical dilation; (2) need for mechanical dilation and ease of dilation if&#xD;
      required; (3) ability to complete the abortion procedure without further cervical&#xD;
      preparation; (4) complications; (5) provider variables including ease of procedure and&#xD;
      satisfaction with cervical preparation; (6) patient variables including pre-operative side&#xD;
      effects, post-operative pain, and acceptability&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators compared two doses and intervals of buccal misoprostol for cervical&#xD;
      preparation before surgical abortion at 13 to 16 weeks' gestation. This blinded randomized&#xD;
      trial compared 400 mcg misoprostol administered 3 hours and 600 mcg administered 1.5 hours&#xD;
      before abortion. The investigators analyzed results for the primary outcome (procedure time)&#xD;
      using a non-inferiority limit of 3 or more minutes. The investigators tested two separate&#xD;
      non-inferiority hypotheses each powered at 95% (2.5% confidence interval) for two gestational&#xD;
      age groups: 13.0-14.3 and 14.4-15.6 weeks. Assuming 10% withdrawals, the investigators&#xD;
      required 118 participants. Secondary outcomes included mechanical dilation, complications,&#xD;
      provider satisfaction, and patient side effects and acceptability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>procedure time</measure>
    <time_frame>day of abortion procedure</time_frame>
    <description>Operative time defined as time from speculum in vagina to speculum out of vagina.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Abortion, Induced</condition>
  <arm_group>
    <arm_group_label>400 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receives 400 mcg of misoprostol 3 hours prior to the procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>600 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receives 600 mcg of misoprostol 90 minutes prior to the procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol 400 mcg 3 hours prior to procedure</intervention_name>
    <description>Misoprostol 400 mcg 3 hours prior to D&amp;E procedure</description>
    <arm_group_label>400 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol 600 mcg 90 minutes prior to procedure</intervention_name>
    <description>Misoprostol 600 mcg 90 minutes prior to D&amp;E procedure</description>
    <arm_group_label>600 mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age and older&#xD;
&#xD;
          -  Eligible for pregnancy termination at Planned Parenthood of NYC&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Reports active bleeding, severe pain, or symptoms of spontaneous labor at enrollment&#xD;
&#xD;
          -  Intrauterine fetal demise identified on pre-operative ultrasound&#xD;
&#xD;
          -  Allergy to misoprostol&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gillian Dean, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Planned Parenthood of NYC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Planned Parenthood of New York City - Margaret Sanger Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>October 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2014</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

